In brief
- This is the first published case where a laboratory confirmed the substance ingested was ETH-LAD, the N-ethyl derivative of LSD.
- The patient, an adolescent, presented with agitation and aggression, loss of consciousness, traumatic injuries, metabolic disturbances, and persistent psychosis; he was hospitalized for seventeen days.
- The serum concentration was 38 ng/mL. A single case does not indicate how frequently this occurs, but it serves as a reminder that an analog is not the original molecule by another name.
Dozens of LSD analogs have been described, yet only a few have been thoroughly studied. On August 7, the British Journal of Clinical Pharmacology published the first clinical case in which it was analytically confirmed that the substance consumed was ETH-LAD, and the resulting clinical picture did not resemble what one would expect from a dose of LSD.
What happened
The report was authored by professionals from the Poison Information Center in Freiburg and the adolescent medicine department of the university hospital in that city, Germany. An adolescent patient arrived at the hospital with acute agitation and aggression, lost consciousness, and suffered several traumatic injuries, in addition to metabolic disturbances. He required intensive care and remained hospitalized for seventeen days; upon discharge, he was transferred to a psychiatric unit because the psychosis had not remitted. Blood analysis measured 38 nanograms of ETH-LAD per milliliter of serum.
Why laboratory confirmation matters
Most reports on new psychoactive substances rely on the accounts of those who have taken them, and the margin for error there is enormous: a blotter paper does not carry a label, and what is sold as a specific lysergamide may be another. Having a laboratory identify and quantify the substance makes this case a benchmark for medical literature. The authors state it bluntly in their conclusion: healthcare personnel should be aware that ETH-LAD, unlike LSD, can cause severe toxic effects requiring intensive care.
What it implies
One case is not a statistic. We do not know how many people take ETH-LAD without incident, nor what role the dose, context, or the patient’s age played here, and the report itself does not clarify this. What it does provide is useful information for those who choose to use these substances: LSD analogs share a structure but not necessarily potency, duration, or risk profile, so applying LSD reference doses is an assumption, not a fact. We have previously reported that some of these analogs end up converting into LSD in the body, while others do not. Testing substances when possible, starting lower than planned, not being alone, and seeking medical help without fear if something goes wrong remain the basic tools of harm reduction, precisely because the market changes faster than science can describe it.
Source
- Nadler J, Sommer M, Zschiesche A, Stürzebecher A, Grumann C, Auwärter V, Hermanns-Clausen M. An ETH-LAD trip with unfavourable consequences: A case report. British Journal of Clinical Pharmacology, August 7, 2026 (PMID 42568216).
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
